A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Phase 1/2
270
about 6 years
18+
4 sites in AL, FL, NJ +1
About this study
This trial is testing a treatment called MK-3120 for people with advanced solid tumors. The goal is to see if this treatment is safe and well-tolerated by participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive MK-3120
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Secondary: AUC of MK-3120 Free Payload, AUC of MK-3120 Total Antibody (TAb), Area Under the Concentration-Time Curve (AUC) of MK-3120 Antibody-Drug Conjugate (ADC), Cmax of MK-3120 Free Payload, Cmax of MK-3120 TAb, Duration Of Response (DOR) Per RECIST 1.1 as Assessed by the Investigator, Maximum Concentration (Cmax) of MK-3120 ADC, Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the Investigator
Oncology